Ivantis Garners $25,000,000 Series B Round

  • Feed Type
  • Date
    9/23/2014
  • Company Name
    Ivantis
  • Mailing Address
    38 Discovery Irvine, CA 92618 USA
  • Company Description
    Ivantis, Inc. is a company dedicated to the development of new and innovative solutions for glaucoma. Current therapies for primary open angle glaucoma (POAG) include eye drops, laser therapy, and surgery. But each of these has its limitations. Glaucoma remains the leading cause of blindness worldwide, in need of better treatment alternatives. It is our goal to develop new and effective solutions for ophthalmology specialists and the 70 million people worldwide who are affected by this debilitating and sight-stealing disease.
  • Website
    http://www.ivantisinc.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $25,000,000
  • Transaction Round
    Series B
  • Proceeds Purposes
    The funds will support the Company’s multiple ongoing clinical trials, including the US pivotal trial, and is expected to take the Company through U.S. approval.
  • M&A Terms
  • Venture Investor
  • Venture Investor
  • Venture Investor
  • Venture Investor
  • Venture Investor
  • Venture Investor
  • Venture Investor
  • Venture Investor

Trending on Xconomy